ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabbagh, A. H.
Right arrow Articles by Gabrhel, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabbagh, A. H.
Right arrow Articles by Gabrhel, W.

The Annals of Thoracic Surgery, Vol 37, 466-468, Copyright © 1984 by The Society of Thoracic Surgeons


ARTICLES

Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass

AH Sabbagh, GK Chung, P Shuttleworth, BJ Applegate and W Gabrhel

The reasons for the highly variable response of patients to heparin remain incompletely understood. Empirical maintenance of the activated clotting time (ACT) at levels of 400 to 480 seconds appears to be safe for cardiopulmonary bypass (CPB). For patients with ACT responses lower than predicted for initial heparin doses, titration with additional heparin has been customary. In 44 patients undergoing cardiopulmonary bypass, 20 patients were identified as having initial ACTs of 300 seconds or less after receiving 300 units per kilogram of heparin. In 11 of them, ACTs were titrated to 400 to 480 seconds with additional heparin. Nine were given 2 units of fresh frozen plasma shortly after institution of CPB. In this group, there was significant augmentation of the ACT immediately after infusion of plasma. No differences in total heparin dosages given during CPB were found between 24 control patients with initially acceptable ACTs and the group receiving fresh frozen plasma. In contrast, more heparin was necessary in the patients with a low ACT titrated with heparin alone. Data also indicated that protamine sulfate requirements were substantially lower after administration of plasma than were those in either the control or the heparin-titrated, low ACT group. Fresh frozen plasma appears to "normalize" the heparin-ACT dose-response curve in heparin-resistant patients and to lessen total heparin requirements during CPB.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
B. D. Spiess
Treating heparin resistance with antithrombin or fresh frozen plasma.
Ann. Thorac. Surg., June 1, 2008; 85(6): 2153 - 2160.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
S. Bar-Yosef, H. B. Cozart, B. Phillips-Bute, J. P. Mathew, and H. P. Grocott
Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery: [L'heparine de bas poids moleculaire en preoperatoire reduit la reponse a l'heparine pendant la chirurgie cardiaque]
Can J Anesth, February 1, 2007; 54(2): 107 - 113.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
S. T. Morozowich, B. S. Donahue, and I. J. Welsby
Genetics of coagulation: considerations for cardiac surgery.
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 297 - 313.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M.S. Avidan, J.H. Levy, H. van Aken, R.O. Feneck, R.D. Latimer, E. Ott, E. Martin, D.E. Birnbaum, L.J. Bonfiglio, D.K. Kajdasz, et al.
Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 107 - 113.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. H. Levy, F. Montes, F. Szlam, and C. D. Hillyer
The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy
Anesth. Analg., May 1, 2000; 90(5): 1076 - 1079.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
M Ranucci, A Cazzaniga, G Isgro, A Ditta, A Boncilli, M Cotza, and S Brozzi
Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients
Perfusion, September 1, 1999; 14(5): 357 - 362.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. S. Weisinger and J. H. Levy
Current Hematologic Issues in Cardiac Surgery and Cardiopulmonary Bypass
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1998; 2(4): 259 - 271.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
P. Robbins, M. Forrest, and D. Royston
Hypercoagulable States
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 295 - 318.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
M. S. Irani
Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients
Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 103 - 106.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. J. Despotis, J. H. Joist, D. Joiner-Maier, A. L. Alsoufiev, A. N. Triantafillou, L. T. Goodnough, S. A. Santoro, and D. G. Lappas
Effect of Aprotinin on Activated Clotting Time, Whole Blood and Plasma Heparin Measurements
Ann. Thorac. Surg., January 1, 1995; 59(1): 106 - 111.
[Abstract] [Full Text]


Home page
PerfusionHome page
C. Aren
Review article : Heparin and protamine during cardiac surgery
Perfusion, July 1, 1989; 4(3): 171 - 181.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1984 by The Society of Thoracic Surgeons.